76
The issuer is solely responsible for the content of this announcement.
- Revenue increases by +12% compared to the second half of 2024 to €813.4 million (H2 2024: €727.0 million)
- EBITDA increases by +24% compared to the second half of 2024 to €337.6 million (H2 2024: €272.1 million)
- EBITDA margin remains at an industry-leading level of 42%
- Number of employees grows to 789, an increase of 8% (H1 2024: 730)
The globally active CHEPLAPHARM Group, a world leader in the acquisition of original preparations from the research-based…